S
Stephen Sutton
Researcher at University of Cambridge
Publications - 421
Citations - 23035
Stephen Sutton is an academic researcher from University of Cambridge. The author has contributed to research in topics: Randomized controlled trial & Smoking cessation. The author has an hindex of 70, co-authored 412 publications receiving 20781 citations. Previous affiliations of Stephen Sutton include Cooperative Research Centre & James Cook University.
Papers
More filters
Journal ArticleDOI
Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: a randomised controlled trial.
Theresa M. Marteau,Paul Aveyard,Marcus R. Munafò,A Toby Prevost,Gareth J Hollands,David Armstrong,Stephen Sutton,Chloe Hill,Elaine C. Johnstone,Ann Louise Kinmonth +9 more
TL;DR: Informing smokers their oral dose of NRT was tailored to genotype not phenotype had a small, statistically non-significant effect on 28-day adherence to NRT, and among those still smoking at six months, there was no evidence that saying NRT is tailored togenotype adversely affected motivation to make another quit attempt.
Journal ArticleDOI
What motivates interest in attending a familial cancer genetics clinic
Lynn Fraser,S Bramald,Cyril Chapman,Cheri Chu,Victoria Cornelius,F Douglas,Anneke Lucassen,A Nehammer,Stephen Sutton,Marialena Trivella,Shirley Hodgson,Shirley Hodgson +11 more
TL;DR: Personal motivation for referral is clearly different for those who have had a diagnosis of cancer and for those with children, compared to unaffected and childless people, and is characterised by altruistic concern for other family members rather than a perception of increased personal risk.
Journal ArticleDOI
Predictors of suboptimal glycaemic control in type 2 diabetes patients: The role of medication adherence and body mass index in the relationship between glycaemia and age
Alexander Nagrebetsky,Simon J. Griffin,Ann Louise Kinmonth,Stephen Sutton,Anthea Craven,Andrew Farmer,Andrew Farmer +6 more
TL;DR: The lower HbA(1c) achieved from greater adherence to glucose lowering treatment is comparable to that achieved with additional medication, and is not explained by better adherence, but may partly relate to lower BMI.
Journal ArticleDOI
Effect of communicating DNA based risk assessments for Crohn’s disease on smoking cessation: randomised controlled trial
Gareth J Hollands,Sophia C L Whitwell,Richard A Parker,Natalie J. Prescott,Alastair Forbes,Jeremy D. Sanderson,Christopher G. Mathew,Cathryn M. Lewis,Sally Watts,Stephen Sutton,David Armstrong,Ann Louise Kinmonth,A Toby Prevost,Theresa M. Marteau +13 more
TL;DR: Among relatives of patients with Crohn’s disease, feedback of DNA based risk assessments does not motivate behaviour change to reduce risk any more or less than standard risk assessment, and these findings accord with those across a range of populations and behaviours.